Company news
Cosciens Biopharma Inc. (TSX:CSCI) news
Cosciens Biopharma Inc. news releases on 6ix. Latest, Feb 3, 2012: Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration…
Press releases — page 5
Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting
February 3, 2012
Aeterna Zentaris: Updated Interim Phase 1 Trial Results for AEZS-108 in Prostate Cancer To Be Presented at Upcoming ASCO GCS Meeting in San Francisco
January 26, 2012
Aeterna Zentaris Announces Collaboration with Ventana Medical Systems, Inc. to Develop Companion Diagnostic in Cancer for AEZS-108
January 5, 2012
Aeterna Zentaris Partner, Yakult Honsha, Initiates Phase 1/2 Trial with Perifosine in Colorectal Cancer in Japan
January 3, 2012
Aeterna Zentaris: Encouraging Clinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting
December 13, 2011
Aeterna Zentaris: Encouraging Preclinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting
December 12, 2011
Aeterna Zentaris Presents Positive Preclinical Data in Breast Cancer on AEZS-131, a Highly Selective Erk 1/2 Inhibitor, at San Antonio Breast Cancer Symposium
December 9, 2011
Aeterna Zentaris: Presentations on Perifosine Scheduled at Upcoming ASH Meeting in San Diego, California
December 5, 2011
Aeterna Zentaris: FDA Grants IND to Investigator at Baylor College of Medicine for Phase 2A Trial with AEZS-130 in Cancer Cachexia
November 28, 2011
Aeterna Zentaris and Hikma Pharmaceuticals Sign a Commercialization and Licensing Agreement for Lead Oncology Compound, Perifosine, for Middle East and North Africa (MENA) Region
November 23, 2011
Aeterna Zentaris to Present at Upcoming Piper Jaffray and Oppenheimer Healthcare Conferences in New York
November 22, 2011
Aeterna Zentaris Presents Encouraging Preclinical Data for Disorazol Z (AEZS-137) at AACR-NCI-EORTC Conference
November 16, 2011
Aeterna Zentaris Reports Third Quarter 2011 Financial and Operating Results
November 10, 2011
Aeterna Zentaris to Report Third Quarter 2011 Financial and Operating Results on November 10, 2011
November 3, 2011
Aeterna Zentaris to Present at Upcoming Major Cancer Conferences
November 1, 2011
Aeterna Zentaris: FDA Grants IND to Investigator at University of Miami School of Medicine for Phase 2 Trial with AEZS-108 in Triple-Negative Breast Cancer
October 25, 2011
Phase 1/2 Clinical Trial Results of Perifosine Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
October 13, 2011
Aeterna Zentaris: Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of Perifosine Plus Capecitabine in Patients with Metastatic Colorectal Cancer
October 5, 2011
Aeterna Zentaris Announces Interim Data for its Phase 1/2 Trial with AEZS-108 in Prostate Cancer at ESMO Congress - AEZS-108 well tolerated at all dose levels / Early evidence of anti-tumor activity
September 26, 2011
Aeterna Zentaris to Present at Upcoming 6th Annual JMP Securities Healthcare Conference in New York
September 21, 2011
Aeterna Zentaris Presents Positive Final Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ESGO Meeting in Milan, Italy
September 14, 2011
Aeterna Zentaris to Present at Two Upcoming Investment Conferences in the United States
September 1, 2011
Aeterna Zentaris Announces Completion of Interim Analysis by Data Safety Monitoring Board for the Phase 3 Study of Perifosine for the Treatment of Refractory Advanced Colorectal Cancer
August 31, 2011
Aeterna Zentaris Announces Favorable Top-Line Results of Completed Phase 3 Study on AEZS-130 as First Oral Diagnostic Test for Adult Growth Hormone Deficiency
August 30, 2011
Aeterna Zentaris to Present Poster on Novel Oral Anticancer Erk Inhibitors at Upcoming American Chemical Society's National Meeting
August 23, 2011
Aeterna Zentaris Reports Second Quarter 2011 Financial and Operating Results
August 10, 2011
Aeterna Zentaris to Announce Second Quarter 2011 Financial and Operating Results on August 10, 2011
August 3, 2011
Aeterna Zentaris to Present at Upcoming Canaccord Genuity 30th Annual Growth Conference in Boston
August 2, 2011
Aeterna Zentaris Announces Completion of Patient Recruitment for Phase 3 Trial with Perifosine in Refractory Advanced Colorectal Cancer
July 27, 2011
Aeterna Zentaris Completes Phase 3 Study on AEZS-130 as First Oral Diagnostic Test for Adult Growth Hormone Deficiency
July 26, 2011
Aeterna Zentaris Successfully Reached a Key Milestone in the Non-Clinical Development of its Oral Prostate Cancer Vaccine Candidate, AEZS-120
July 20, 2011
Aeterna Zentaris Announces Poster Presentation on Final Phase 2 Results for AEZS-108 in Endometrial Cancer at Upcoming European Society of Gynaecological Oncology Meeting
July 18, 2011
Aeterna Zentaris Granted Patent for Perifosine by European Patent Office
July 12, 2011
Aeterna Zentaris Announces Poster Presentation of Phase 1/2 Results for AEZS-108 in Prostate Cancer at Upcoming European Society of Medical Oncology Congress
July 7, 2011
Aeterna Zentaris to Present at Upcoming BioFinance 2011 Conference in Toronto
May 25, 2011
Aeterna Zentaris Reports First Quarter 2011 Financial and Operating Results
May 18, 2011
Aeterna Zentaris to Announce First Quarter 2011 Financial and Operating Results and Hold Annual Shareholder Meeting on May 18, 2011
May 11, 2011
Aeterna Zentaris to Present at Upcoming 10th Annual JMP Securities Research Conference in San Francisco
May 4, 2011
Aeterna Zentaris Announces Results on AEZS-131, a Highly Selective Erk 1/2 Inhibitor Anticancer Compound at American Association for Cancer Research Annual Meeting
April 5, 2011